机器人胸腺切除术治疗恶性疾病的中期结果
该研究回顾性分析单术者前瞻性数据库2010年1月至2019年6月计划行机器人切除的恶性疾病患者,其中84例(39%)接受机器人胸腺切除术。胸腺瘤最常见(68%),肿瘤中位大小4.7 cm,中位手术时间81.5分钟,98.8%实现R0切除,主要并发症3.5%,无30天或90天死亡。胸腺瘤患者中位随访32个月,同侧胸复发率1.8%。结论认为机器人胸腺切除术安全且围术期结果良好,但需更长期随访评估肿瘤学耐久性。
要点
- 机器人胸腺切除术治疗恶性疾病安全,围术期并发症和死亡率低。
- 即使肿瘤较大,机器人入路仍可实现高比例R0切除(98.8%)。
- 胸腺瘤患者中期随访局部复发率低(1.8%),但需更长期肿瘤学评估。
核心结论
- 机器人胸腺切除术治疗恶性疾病安全,围术期结果优异,R0切除率高,胸腺瘤中期局部复发率低。
研究设计与样本
- 单术者前瞻性数据库回顾性分析,纳入2010年1月至2019年6月计划行机器人切除的恶性疾病患者,共84例接受机器人胸腺切除术。
主要发现
- 胸腺瘤为最常见病理(68%),肿瘤中位大小4.7 cm(IQR 2.9-6.3),中位手术时间81.5分钟(IQR 64-104)。
- 98.8%患者实现R0切除,2例(2.3%)计划外但择期中转开胸,其中1例需体外循环。
- 中位住院1天(范围0-9),再入院1例(1.2%),主要并发症3例(3.5%),无30天或90天死亡。
- 胸腺瘤患者中位随访32个月(范围1-98),1例(1.8%)出现同侧胸复发,无患者死亡。
临床怎么用
- 对于恶性胸腺疾病,机器人胸腺切除术可作为安全术式,实现高R0切除率和低并发症。
- 术后住院时间短,中期胸腺瘤局部复发率低,但需长期随访监测肿瘤学结果。
局限性
- 单术者回顾性研究,样本量有限,随访时间中期,需更长期分析确定肿瘤学耐久性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are limited reports on robotic thymectomy for malignant disease. Our objectives are to review our experience and midterm outcomes. METHODS: We reviewed a single-surgeon prospective database for patients who underwent planned robotic resection for malignancy from January 2010 to June 2019. RESULTS: Two hundred thirteen patients underwent resection of an anterior mediastinal mass, all of which were planned for a robotic approach. Of these, 84 (39%) underwent robotic thymectomy for malignant disease. Thymoma was the most common pathology resected (68%). Median tumor size was 4.7 cm (interquartile range, 2.9-6.3), and median operative time was 81.5 minutes (interquartile range, 64-104). All except 1 patient had a complete (R0) resection (98.8%). There were 2 (2.3%) unplanned but elective conversions to open surgery, 1 of which required cardiopulmonary bypass. Median length of stay was 1 day (range, 0-9) with 1 readmission (1.2%). Major morbidity occurred in 3 patients (3.5%), and there were no 30- or 90-day mortalities. In patients with thymoma, follow-up was complete at a median of 32 months (range, 1-98), and 1 patient (1.8%) had an ipsilateral chest recurrence. To date there have been no patient deaths. CONCLUSIONS: Robotic thymectomy for patients with malignant disease is safe with excellent perioperative outcomes. A robotic approach achieves a high rate of complete R0 resection, even for larger tumors. For patients with thymoma local recurrence is low after midterm follow-up, but longer-term analysis is needed to determine oncologic durability.
引用
- Geraci TC, Ferrari-Light D, Pozzi N, et al. Midterm Results for Robotic Thymectomy for Malignant Disease. Ann Thorac Surg. 2020. PMID: 32926846. doi:10.1016/j.athoracsur.2020.06.111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。